Search Within

Helen Hancock

  1. "Dermatology Service"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (1)
Groups
  1. Advanced Practice Providers (8)
  2. Center for Hematologic Malignancies (8)
  3. Department of Medicine (8)
  4. Dermatology (8)
  5. Dermatology Service (8)
  6. Division of Subspecialty Medicine (8)

More Groups

People
  1. Alison Moskowitz (8)
  2. Natasha Galasso (8)
  3. Patricia Myskowski (8)
  4. Steven Horwitz (8)
  5. Theresa Davey (8)
  6. Nivetha Ganesan (7)

More People

Years
  1. 2023 (1)
  2. 2021 (3)
  3. 2020 (1)
  4. 2019 (1)
  5. 2018 (2)
Publications
  1. Blood (5)
  2. Hematological Oncology (2)
  3. Cancer Research (1)
Publishers
  1. American Society of Hematology (5)
  2. Wiley Blackwell (2)
  3. American Association for Cancer Research (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Reduced dose brentuximab vedotin for mycosis fungoides appears to prolong response duration by balancing efficacy and tolerability
    Meeting Abstract

    Munayirji, B.; Khan, N.; Myskowski, P.; Geller, S.; Noor, S.; Kheterpal, M. K.; Davey, T.; Hancock, H.; Perez, L.; Miller, T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas
    Meeting Abstract

    Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Multispectral immunofluorescence identifies pS6 as a biomarker of intrinsic resistance to ruxolitinib in patients with relapsed/refractory T-cell lymphomas
    Meeting Abstract

    Ghione, P.; Moskowitz, A.; Kumar, P.; Knezevic, A.; Seshan, V.; Jacobsen, E.; Ruan, J.; Schatz, J.; Noor, S.; Myskowski, P.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E. D.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Hancock, H.; Davey, T.; Obadi, O.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • The combination of duvelisib, a PI3K-δ,γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Jacobsen, E. D.; Mehta-Shah, N.; Khodadoust, M. S.; Fisher, D. C.; Myskowski, P.; Wang, E. B. K.; Tawa, M.; Davey, T.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Durable responses observed with JAK inhibition in T-cell lymphomas
    Meeting Abstract

    Moskowitz, A. J.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Obadi, O.; Motylinski, K.; Jarjies, C.; Galasso, N.; Hancock, H.; Davey, T.; more...
    Blood (2018)

    Fulltext@MSK | Save